![](./img/slider/slider_01_animation_big.png)
![](./img/slider/slider_01_animation_small.png)
We are
an emerging leader in hematology/oncology and are committed to making a profound impact in the lives of patients - with the ongoing commercialization of Monjuvi® and the clinical development of pelabresib in myelofibrosis.
![](./img/slider/slider_02_animation.png)
Monjuvi
Since launch, approximately 2,000 patients have been treated with our cancer immunotherapy in the U.S. Monjuvi, in combination with lenalidomide, provides a paradigm shift in treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Beyond the current indication, approved under accelerated approval, we are developing Monjuvi in additional hematological indications.
![](./img/slider/slider_03_animation.png)
Pelabresib
Our aspiration for our most exciting new pipeline asset is to potentially change the standard of care in myelofibrosis, a bone marrow cancer for which only limited treatment options are available. Pelabresib is currently being explored in a phase 3 trial, and we expect the data in the first half of 2024.